Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients (URRAH)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Pavia, Italy, 27100
- Fondazione IRCCS Policlinico San Matteo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Lung transplanted patients who receive diagnosis of chronic lung allograft dysfunction (CLAD)
|
|
Heart transplanted patients who receive diagnosis of cardiac allograft vasculopathy (CAV)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
identification the primary mechanism of action of ECP in CLAD and CAV by analyzing biological markers (such as relative expression levels of microRNAs, potentially involved in immune regulation), associated to response to a 6 month-ECP treatment course
Time Frame: After 6 months from ECP treatment
|
After 6 months from ECP treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between up-regulation or down-regulation of miRNAs at 6 months of therapy respect to baseline and other immune variables (regulatory T cells activation and differentiation, inflammatory cytokines levels and presence of anti-HLA antibodies)
Time Frame: After 6 months of therapy
|
After 6 months of therapy
|
|
|
Evaluation the effectiveness of ECP
Time Frame: After 2 years of follow-up from ECP
|
Evaluation the effectiveness of ECP in reducing cardiovascular mortality and preventing percutaneous myocardial revascularization and hospitalization by cardiovascular causes at 2 years of follow-up in comparison to a control population of heart transplant recipients with CAV included in our historical archive
|
After 2 years of follow-up from ECP
|
|
Effect of ECP on progression of myocardial fibrosis evaluated at CMR
Time Frame: After 6 months of treatment
|
After 6 months of treatment
|
|
|
Effect of ECP on ventricular function evaluated at echocardiography
Time Frame: After 6 months of treatment
|
After 6 months of treatment
|
|
|
Trend of heart failure biomarkers (NT proBNP or BNP) after 6 months of treatment
Time Frame: After 6 months of treatment
|
After 6 months of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- URRAH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.